普罗布考联合他汀类药物治疗颈动脉斑块的meta分析

doi:10.3969/j.issn.1673-5765.2024.03.008

摘要/Abstract

摘要： 目的探究普罗布考联合他汀类药物治疗颈动脉斑块的疗效。
方法以“普罗布考”“他汀”“颈动脉”为中文关键词，检索中文数据库中国知网、维普网、万方数据库，以“carotid artery”“probucol”“statins”为英文关键词，检索英文数据库PubMed、Cochrane Library、Embase，筛选普罗布考联合他汀类药物治疗颈动脉斑块的随机对照试验。检索时间为数据库建立至2023年12月17日。以单用他汀类药物治疗为对照组，他汀类药物联合普罗布考治疗为联合治疗组。参照Cochrane偏倚风险评估对纳入的研究进行质量评价。主要结局指标包括颈动脉内-中膜厚度
（intima-media thickness，IMT），次要结局指标包括TC水平、hs-CRP水平、卒中事件发生等。采用RevMan 5.1软件进行meta分析。
结果最终纳入11项随机对照试验，共纳入3251例患者。meta分析显示，在降低IMT方面，联合治疗组优于对照组[标准化均数差（standardized mean difference，SMD）-0.93，95%CI -1.66～-0.20，P＜0.001]；
在降低TC水平方面，联合治疗组优于对照组（SMD -1.08，95%CI -1.60～-0.55，P＜0.001）；在降低hs-CRP水平方面，两组差异无统计学意义（SMD -1.22，95%CI -2.48～0.04，P=0.060）；在减少卒中事件发生方面，联合治疗组优于对照组（RR 0.34，95%CI 0.17～0.65，P=0.001）。
结论普罗布考联合他汀类药物治疗颈动脉斑块疗效更优，可降低患者的TC水平，并减少卒中事件发生。

文章导读： 本文探究了普罗布考联合他汀类药物治疗对颈动脉斑块患者的IMT厚度、稳定性等指标的影响，改善脂代谢指标、炎症指标的情况，以及对此类患者后续卒中发生风险的影响，为患者提供了更多的用药选择。

关键词: 普罗布考; 他汀; 颈动脉斑块; 颈动脉内-中膜厚度; 缺血性卒中

Abstract: Objective To investigate the efficacy of probucol combined with statins in the treatment of carotid plaque.
Methods Using “probucol” “statin” “carotid artery” as the keywords, Chinese databases CNKI, VIP and WanFang, English databases PubMed, Cochrane Library and Embase were searched. Screening randomized controlled trials of probucol combined with statins for carotid plaque. The search period was from the establishment of the database until December 17, 2023. Statin therapy alone was the control group, and statin therapy combined with probucol was the combined group. The quality of included studies was assessed with reference to Cochrane bias risk assessment. The main outcome measures included the average carotid artery intima-media thickness (IMT), secondary outcome indicators included TC, hs-CRP, stroke events, etc. Meta-analysis was performed using RevMan 5.1 software.
Results Eleven randomized controlled trials with a total of 3251 patients were included. Meta-analysis showed that the combined group was superior to the control group in reducing IMT [standardized mean difference (SMD) -0.93, 95%CI -1.66--0.20, P＜0.001]. The combined group was better than the control group in reducing TC level (SMD -1.08, 95%CI -1.60--0.55, P＜0.001). There was no significant difference in reducing hs-CRP level between the two groups (SMD -1.22, 95%CI -2.48-0.04, P=0.060). The combined group was superior to the control group in reducing stroke events (RR 0.34, 95%CI 0.17-0.65, P=0.001).
Conclusions Probucol combined with statins is more effective in the treatment of carotid plaque, and can reduce the level of TC and the incidence of stroke events.

Key words: Probucol; Statin; Carotid plaque; Carotid artery intima-media thickness; Ischemic stroke

中图分类号:

陈思嘉, 潘培炎, 陈思琪, 彭菲, 米东华. 普罗布考联合他汀类药物治疗颈动脉斑块的meta分析[J]. 中国卒中杂志, 2024, 19(3): 299-309.

CHEN Sijia, PAN Peiyan, CHEN Siqi, PENG Fei, MI Donghua. The Effect of Probucol Combined with Statins in the Treatment of Carotid Plaque: A Meta-Analysis[J]. Chinese Journal of Stroke, 2024, 19(3): 299-309.

参考文献

[1] BOS D，ARSHI B，van den BOUWHUIJSEN Q J A，et al. Atherosclerotic carotid plaque composition and incident stroke and coronary events[J]. J Am Coll Cardiol，2021，77（11）：1426-1435.
[2] TOUBOUL P J，HENNERICI M G，MEAIRS S，et al. Mannheim carotid intima-media thickness and plaque consensus（2004-2006-2011）. An update on behalf of the advisory board of the 3rd，4th and 5th watching the risk symposia，at the 13th，15th and 20th European Stroke Conferences，Mannheim，Germany，2004，Brussels，Belgium，2006，and Hamburg，Germany，2011[J]. Cerebrovasc Dis，2012，34（4）：290-296.
[3] SABA L，SAAM T，JÄGER H R，et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications[J]. Lancet Neurol，2019，18（6）：559-572.
[4] WILLEIT P，TSCHIDERER L，ALLARA E，et al. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk[J]. Circulation，2020，142（7）：621-642.
[5] MACH F，BAIGENT C，CATAPANO A L，et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk[J]. Eur Heart J，2020，41（1）：111-188.
[6] BONATI L H，JANSEN O，DE BORST G J，et al. Management of atherosclerotic extracranial carotid artery stenosis[J]. Lancet Neurol，2022，21（3）：273-283.
[7] YAMASHITA S，MASUDA D，HARADA-SHIBA M，et al. Effectiveness and safety of lipid-lowering drug treatments in japanese patients with familial hypercholesterolemia：familial hypercholesterolemia expert forum（FAME）study[J]. J Atherosclerosis Thrombs，2022，29（5）：608-638.
[8] OSAKA N. Naso-temporal differences in human reaction time in the peripheral visual field[J]. Neuropsychologia，1978，16（3）：299-303.
[9] KANG H J，KIM M H，SUNG J，et al. Effect of probucol and/or cilostazol on carotid intima media thickness in patients with coronary heart disease：a randomized，multicenter，multinational study[J]. J Atheroscler Thromb，2021，28（2）：124-136.
[10] YAMASHITA S，MASUDA D，OHAMA T，et al. Rationale and design of the PROSPECTIVE trial：probucol trial for secondary prevention of atherosclerotic events in patients with prior coronary heart disease[J]. J Atheroscler Thromb，2016，23（6）：746-756.
[11] 岳蕴华，白旭东，张小宁，等. 普罗布考联合阿托伐他汀对脑梗死患者血清hs-CRP、ox-LDL、MMP-9水平及颈动脉斑块的影响[J]. 中国神经精神疾病杂志，2014，40（11）：641-645.
YUE Y H，BAI X D，ZHANG X N，et al. Effects of the combination therapy of probucol with atorvastatin on serum hs-CRP，ox-LDL and MMP-9 levels and carotid plaque in patients with acute cerebral infarction[J]. Chin J Nervous Mental Dis，2014，40（11）：641-645.
[12] 宋伟慧. 瑞舒伐他汀联合普罗布考对急性脑梗死患者颈动脉斑块的作用[D]. 青岛：青岛大学，2019.
SONG W H. Effect of rosuvastatin combined with probucol on carotid plaque in patients with acute cerebral infarction[D]. Qingdao：Qingdao University，2019.
[13] 王喜福，叶明，李远竞，等. 普罗布考联合瑞舒伐他汀对高脂血症患者颈动脉斑块及炎性因子的影响[J]. 安徽医药，2013，17（5）：836-838.
WANG X F，YE M，LI Y J，et al. Effects of probucol and rosuvastatin on carotid artery plaques and inflammatory factors in patients with hyperlipidemia[J]. Anhui Medical and Pharmaceutical Journal，2013，17（5）：836-838.
[14] 岳伟，张雅静，刘淑玲，等. 普罗布考对大动脉粥样硬化性脑梗死预后的影响[J]. 中国生化药物杂志，2016，36（1）：50-52.
YUE W，ZHANG Y J，LIU S L，et al. Prognosis effect of probucol on patients with large atherosclerotic cerebral infarction[J]. Chin J Biochem Pharm，2016，36（1）：50-52.
[15] 李俊霞. 普罗布考的干预治疗对ox-LDL、hs-CRP、颈动脉粥样硬化及缺血性脑血管事件的影响[D]. 泰安：泰山医学院，2011.
LI J X. Effect of probucol intervention on ox-LDL，hs-CRP，carotid atherosclerosis and ischemic cerebrovascular events[D]. Taian：Taishan Medical University，2011.
[16] 董晓柳，张利，高秋燕，等. 普罗布考对2型糖尿病患者踝肱指数和颈动脉粥样硬化斑块的影响[J]. 重庆医学，2016，45（31）：4431-4433.
DONG X L，ZHANG L，GAO Q Y，et al. Effect of probucol on ankle-brachial index and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus[J]. Chongqing Medicine，2016，45（31）：4431-4433.
[17] 赵岐，王巍巍，王树国，等. AS治疗和PAS治疗对通化地区缺血性卒中危险因素影响的对比分析[J/OL]. 世界最新医学信息文摘，2017，17：30-31[2023-11-11]. https://doi.org/10.19613/j. cnki.1671-3141.2017.101.016.
ZHAO Q，WANG W W，WANG S G，et al. Comparative analysis of the effect of AS treatment and PAS treatment on risk factors of ischemic stroke in Tonghua area[J/OL]. World Latest Medicine Information，2017，17：30-31[2023-11-11]. https://doi.org/10.19613/j.cnki.1671-3141.2017.101.016.
[18] 朱丽霞，董晓柳，徐士军. 阿托伐他汀联合普罗布考对高血压患者血管弹性的影响[J]. 中国药房，2016，27（23）：3243-3245.
ZHU L X，DONG X L，XU S J. Effects of atorvastatin combined with probucol on the vascular elasticity in patients with hypertension[J]. China Pharmacy，2016，27（23）：3243-3245.
[19] 孟晓萍，王素香，张基昌，等. 普罗布考联合降脂药物对动脉粥样硬化病人的干预治疗[J]. 中华医学杂志，2009，89（28）：1986-1988.
MENG X P，WANG S X，ZHANG J C，et al. Effects of probucol，aspirin and atorvastatin combination therapy upon atherosclerosis[J]. Natl Med J China，2009，89（28）：1986-1988.
[20] WAFA H A，WOLFE C D A，EMMETT E，et al. Burden of stroke in europe[J]. Stroke，2020，51（5）：2418-2427.
[21] CARBALLO-PERICH L，PUIGORIOL-ILLAMOLA D，BASHIR S，et al. Clinical parameters and epigenetic biomarkers of plaque vulnerability in patients with carotid stenosis[J]. Int J Mol Sci，2022，23（9）：5149.
[22] SABA L，NARDI V，CAU R，et al. Carotid artery plaque calcifications：lessons from histopathology to diagnostic imaging[J]. Stroke，2022，53（1）：290-297.
[23] XIE K，ZHAO S，LI X. Efficacy and mechanism of butylphthalide combined with atorvastatin calcium tablets in the diagnosis of cerebral infarction using Iodol/Fe3O4 nanometric contrast agent[J]. J Nanosci Nanotechnol，2020，20（12）：7356-7361.
[24] MIIDA T，SEINO U，MIYAZAKI O，et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL：putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling[J]. Atherosclerosis，2008，200（2）：329-335.
[25] ZHONG J K，GUO Z G，LI C，et al. Probucol alleviates atherosclerosis and improves high density lipoprotein function[J/OL]. Lipids Health Dis，2011，10：210[2024-02-09]. https://doi.org/10.1186/1476-511x-10-210.
[26] 苏波. 普罗布考抗ox-LDL诱导THP-1巨噬细胞凋亡的作用及机制[D]. 衡阳：南华大学，2005.
SU P. Effect and mechanism of probucol on apoptosis of THP-1 macrophages induced by ox-LDL[D]. Hengyang：University of South China，2005.
[27] AUBIN M C，CARRIER M，SHI Y F，et al. Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy[J]. J Cardiovasc Pharmacol，2006，47（5）：702-710.
[28] 巴玉兰. 普罗布考与氧化型低密度脂蛋白相关研究进展[J]. 医学综述，2012，18（9）：1305-1308.
BA Y L. Research progress of probucol and oxidized low-density lipoprotein[J]. Medical Recapitulate，2012，18（9）：1305-1308.
[29] HONG S C，ZHAO S P，WU Z H. Effect of probucol on HDL metabolism and class B type Ⅰ scavenger receptor（SR-BI）expression in the liver of hypercholesterolemic rabbits[J]. Int J Cardiol，2007，115（1）：29-35.
[30] SAWAYAMA Y，SHIMIZU C，MAEDA N，et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial（FAST）[J]. J Am Coll Cardiol，2002，39（4）：610-616.
[31] 黄正桥，刘建，朱莹. 阿托伐他汀钙联合普罗布考治疗动脉粥样硬化的临床观察[J]. 中国药房，2017，28（23）：3220-3223.
HUANG Z Q，LIU J，ZHU Y. Clinical observation of atorvastatin calcium combined with probucol in the treatment of atherosclerosis[J]. China Pharmacy，2017，28（23）：3220-3223.
[32] 孙惠敏. 普罗布考与瑞舒伐他汀联合用药治疗缺血性脑血管疾病疗效分析[J]. 基层医学论坛，2021，25（20）：2892-2894.
SUN H M. Therapeutic effect of probucol combined with rosuvastatin in the treatment of ischemic cerebrovascular diseases[J]. The Medical Forum，2021，25（20）：2892-2894.